Comparative Pharmacology
Head-to-head clinical analysis: SYNALAR HP versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALAR HP versus ZYLET.
SYNALAR-HP vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination (Ophthalmic)